Columbia’s Progesterone Faces FDA Skepticism Over Foreign Data At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.
You may also be interested in...
Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
Company will meet with FDA to determine a path forward now that the agency has issued a “complete response” letter for progesterone vaginal gel 8% for reducing the risk of preterm birth in women with a short cervix, Watson CEO Bisaro says.
Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
Company will meet with FDA to determine a path forward now that the agency has issued a “complete response” letter for progesterone vaginal gel 8% for reducing the risk of preterm birth in women with a short cervix, Watson CEO Bisaro says.
NeurogesX’s Qutenza Potential For Successful Committee Review Hinges On Post Hoc Efficacy Analyses
FDA looks askance at the sponsor’s post hoc analyses showing efficacy for its pain patch (capsaicin 8%) for HIV-associated neuropathic pain 30 minutes after application.